BATF3 and neoplasm: Batf3+ cross-presenting dendritic cells are critical for rapid rejection of highly immunogenic tumors following tumor implantation5 with the response dependent on STING activation in dendritic cells36, and early type I IFN production36,37, resulting in efficient cross presentation and CD8-mediated tumor clearance.